A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is
Febrile neutropenia is one of the frequent complications of systemic antitumor therapy, characterized by high rates of patient mortality, mortality is particularly high in patients with pre-existing cardiovascular disease, renal disease, as well as in the presence of anemia. In addition, the development of febrile neutropenia is associated with a decrease in the dose intensity of chemotherapy, which also has an adverse effect on the long-term results of treatment of patients with a number ofdoi:10.21518/2079-701x-2022-16-22-112-118 fatcat:zo6jgrmbavcpjis7zfdemxbcye